Narayana Hrudayalaya Ltd. has informed the Exchange about Investor Presentation
NH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Narayana Hrudayalaya (Narayana Health) filed its Q3 FY26 investor presentation showing consolidated revenue of ₹21,512 Mn, up 61.2% YoY, driven largely by the UK business consolidated from November 6, 2025. India revenue grew 11.8% YoY to ₹11,796 Mn while Cayman Islands revenue jumped 70% YoY to ₹4,991 Mn. Consolidated EBITDA was ₹3,904 Mn at an 18.2% margin (down from 24.4% YoY) and PAT was ₹1,281 Mn at 6.0% margin; adjusted PAT (excluding one-time UK acquisition cost of ₹757 Mn and exceptional labor code impact of ₹509 Mn) grew 31.6% YoY to ₹2,548 Mn. The company operates 55 facilities with 5,933 operational beds and is pursuing aggressive expansion including greenfield projects in Bangalore and Kolkata (FY28-FY29 targets) and a Raipur expansion, with a bed capacity target of 7,600+. Net debt-to-equity ratio is 0.53 with total borrowings of ₹45,442 Mn, including new UK acquisition debt.
Strong top-line growth from the UK acquisition and steady India business expansion is a positive, but the sharp YoY EBITDA margin compression (24.4% to 18.2%) signals near-term profitability pressure from integration costs. The multi-year capex pipeline signals ambitious growth but will keep leverage elevated in the near term.